Origin and prognostic value of circulating KRAS mutations in lung cancer patients

O. Gautschi, B. Huegli, A. Ziegler, M. Gugger, J. Heighway, D. Ratschiller, P. C. Mack, P. H. Gumerlock, H. J. Kung, R. A. Stahel, D. R. Gandara, D. C. Betticher

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.

Original languageEnglish
Pages (from-to)265-273
Number of pages9
JournalCancer Letters
Volume254
Issue number2
DOIs
Publication statusPublished - Sep 8 2007
Externally publishedYes

Fingerprint

Lung Neoplasms
Mutation
Codon
DNA Sequence Analysis
Restriction Fragment Length Polymorphisms
Neoplasms
Lymphocytes
Polymerase Chain Reaction

Keywords

  • Circulating DNA
  • KRAS
  • Lung cancer
  • Mutation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gautschi, O., Huegli, B., Ziegler, A., Gugger, M., Heighway, J., Ratschiller, D., ... Betticher, D. C. (2007). Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Letters, 254(2), 265-273. https://doi.org/10.1016/j.canlet.2007.03.008

Origin and prognostic value of circulating KRAS mutations in lung cancer patients. / Gautschi, O.; Huegli, B.; Ziegler, A.; Gugger, M.; Heighway, J.; Ratschiller, D.; Mack, P. C.; Gumerlock, P. H.; Kung, H. J.; Stahel, R. A.; Gandara, D. R.; Betticher, D. C.

In: Cancer Letters, Vol. 254, No. 2, 08.09.2007, p. 265-273.

Research output: Contribution to journalArticle

Gautschi, O, Huegli, B, Ziegler, A, Gugger, M, Heighway, J, Ratschiller, D, Mack, PC, Gumerlock, PH, Kung, HJ, Stahel, RA, Gandara, DR & Betticher, DC 2007, 'Origin and prognostic value of circulating KRAS mutations in lung cancer patients', Cancer Letters, vol. 254, no. 2, pp. 265-273. https://doi.org/10.1016/j.canlet.2007.03.008
Gautschi O, Huegli B, Ziegler A, Gugger M, Heighway J, Ratschiller D et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Letters. 2007 Sep 8;254(2):265-273. https://doi.org/10.1016/j.canlet.2007.03.008
Gautschi, O. ; Huegli, B. ; Ziegler, A. ; Gugger, M. ; Heighway, J. ; Ratschiller, D. ; Mack, P. C. ; Gumerlock, P. H. ; Kung, H. J. ; Stahel, R. A. ; Gandara, D. R. ; Betticher, D. C. / Origin and prognostic value of circulating KRAS mutations in lung cancer patients. In: Cancer Letters. 2007 ; Vol. 254, No. 2. pp. 265-273.
@article{cea4361c3aba4ef887d7b7abb01fe91a,
title = "Origin and prognostic value of circulating KRAS mutations in lung cancer patients",
abstract = "Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9{\%} plasma samples and 0{\%} matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78{\%} evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.",
keywords = "Circulating DNA, KRAS, Lung cancer, Mutation",
author = "O. Gautschi and B. Huegli and A. Ziegler and M. Gugger and J. Heighway and D. Ratschiller and Mack, {P. C.} and Gumerlock, {P. H.} and Kung, {H. J.} and Stahel, {R. A.} and Gandara, {D. R.} and Betticher, {D. C.}",
year = "2007",
month = "9",
day = "8",
doi = "10.1016/j.canlet.2007.03.008",
language = "English",
volume = "254",
pages = "265--273",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Origin and prognostic value of circulating KRAS mutations in lung cancer patients

AU - Gautschi, O.

AU - Huegli, B.

AU - Ziegler, A.

AU - Gugger, M.

AU - Heighway, J.

AU - Ratschiller, D.

AU - Mack, P. C.

AU - Gumerlock, P. H.

AU - Kung, H. J.

AU - Stahel, R. A.

AU - Gandara, D. R.

AU - Betticher, D. C.

PY - 2007/9/8

Y1 - 2007/9/8

N2 - Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.

AB - Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.

KW - Circulating DNA

KW - KRAS

KW - Lung cancer

KW - Mutation

UR - http://www.scopus.com/inward/record.url?scp=34547183500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547183500&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2007.03.008

DO - 10.1016/j.canlet.2007.03.008

M3 - Article

VL - 254

SP - 265

EP - 273

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -